In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity.
Passive transfer of antibody may be useful for preexposure prophylaxis against biological agents used as weapons of terror, such as Bacillus anthracis. Studies were performed to evaluate the ability of anthrax antiprotective antigen (anti-PA) and antilethal factor (anti-LF) neutralizing monoclonal antibodies (mAbs) to protect against an anthrax lethal toxin (LeTx) challenge in a mouse model and to identify correlates of immunity to LeTx challenge. Despite having similar affinities for their respective antigens, anti-PA (3F11) and anti-LF (9A11), passive transfer of up to 1.5 mg of anti-PA 3F11 mAb did not provide significant protection when transferred to mice 24 h before LeTx challenge, while passive transfer of as low as 0.375 mg of anti-LF 9A11 did provide significant protection. Serum collected 24 h after passive transfer had LeTx-neutralizing activity when tested using a standard LeTx neutralization assay, but neutralization titers measured using this assay did not correlate with protection against LeTx challenge. However, measurement of LeTx-neutralizing serum responses with an LeTx neutralization assay in vitro employing the addition of LeTx to J774A.1 cells 15 min before the addition of the serum did result in neutralization titers that correlated with protection against LeTx challenge. Our results demonstrate that only the LeTx neutralization titers measured utilizing the addition of LeTx to J774A.1 cells 15 min before the addition of sample correlated with protection in vivo. Thus, this LeTx neutralization assay may be a more biologically relevant neutralization assay to predict the in vivo protective capacity of LeTx-neutralizing antibodies.
Staats
Herman F
HF
Department of Pathology, Box 3712, DUMC, Durham, NC 27710, USA. hfs@duke.edu
Alam
S Munir
SM
Scearce
Richard M
RM
Kirwan
Shaun M
SM
Zhang
Julia Xianzhi
JX
Gwinn
William M
WM
Haynes
Barton F
BF
D000818:Animals; D000881:Anthrax / Q000276:immunology / Q000517:prevention & control*; D000907:Antibodies, Bacterial / Q000276:immunology*; D000911:Antibodies, Monoclonal / Q000276:immunology*; D000915:Antibody Affinity; D000942:Antigens, Bacterial / Q000276:immunology* / Q000633:toxicity; D000992:Antitoxins / Q000276:immunology*; D001408:Bacillus anthracis / Q000276:immunology; D001427:Bacterial Toxins / Q000276:immunology* / Q000633:toxicity; D002460:Cell Line; D002470:Cell Survival; D005260:Female; D007116:Immunization, Passive; D008264:Macrophages / Q000187:drug effects; D051379:Mice; D008807:Mice, Inbred BALB C; D009500:Neutralization Tests
D000907:Antibodies, Bacterial; D000911:Antibodies, Monoclonal; D000942:Antigens, Bacterial; D000992:Antitoxins; D001427:Bacterial Toxins; C030325:anthrax toxin
Infect Immun. 2001 May;69(5):2853-7
11292698
Vaccine. 2000 Sep 15;19(2-3):213-6
10930675
Vaccine. 2001 Apr 30;19(23-24):3241-7
11312020
Infect Immun. 2001 Jul;69(7):4509-15
11401993
J Hum Virol. 2001 Mar-Apr;4(2):55-61
11437315
Vaccine. 2001 Aug 14;19(31):4409-16
11483266
Vaccine. 2001 Sep 14;19(32):4768-73
11535328
Crit Rev Microbiol. 2001;27(3):167-200
11596878
JAMA. 2001 Nov 28;286(20):2549-53
11722268
JAMA. 2001 Nov 28;286(20):2554-9
11722269
JAMA. 2001 Nov 28;286(20):2595-7
11722275
J Virol. 2002 Jan;76(2):517-24
11752142
Infect Immun. 2002 Feb;70(2):544-60
11796581
Infect Immun. 2002 Feb;70(2):702-7
11796602
Nat Biotechnol. 2002 Jun;20(6):597-601
12042864
Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11346-50
12177434
Emerg Infect Dis. 2002 Oct;8(10):1044-7
12396913
Emerg Infect Dis. 2002 Oct;8(10):1048-55
12396914
Emerg Infect Dis. 2002 Oct;8(10):1066-72
12396917
Emerg Infect Dis. 2002 Oct;8(10):1073-7
12396918
Infect Immun. 2003 May;71(5):2373-83
12704107
J Immunol. 2003 Jun 1;170(11):5636-43
12759444
J Clin Invest. 2003 Sep;112(5):670-82
12952916
Nat Biotechnol. 2003 Nov;21(11):1305-6
14555959
Vaccine. 2004 Jan 2;22(3-4):422-30
14670324
Am J Physiol Regul Integr Comp Physiol. 2004 Apr;286(4):R699-709
14715494
Hum Antibodies. 2003;12(4):129-35
15156101
Infect Immun. 2004 Jun;72(6):3276-83
15155630
AIDS Res Hum Retroviruses. 2004 Aug;20(8):836-45
15320988
Infect Immun. 2004 Nov;72(11):6313-7
15501759
Diabetes. 1981 Mar;30(3):226-30
7009271
Methods Enzymol. 1983;103:459-69
6669042
J Exp Med. 1984 Apr 1;159(4):1117-31
6323615
J Immunol. 1984 Sep;133(3):1241-9
6205074
J Immunol. 1985 Jan;134(1):250-7
2578044
J Immunol. 1985 Jul;135(1):247-54
2987346
Hybridoma. 1986 Spring;5(1):21-31
2420699
Vox Sang. 1987;52(3):236-43
3474823
Infect Immun. 1988 Jul;56(7):1807-13
3384478
Infect Immun. 1990 Jun;58(6):1606-13
2111283
Infect Immun. 1992 Feb;60(2):662-8
1730501
Arch Virol. 1992;125(1-4):239-50
1642552
AIDS Res Hum Retroviruses. 1997 May 20;13(8):647-56
9168233
Infect Immun. 1997 Dec;65(12):5171-5
9393812
Vaccine. 1998 Jul;16(11-12):1141-8
9682372
J Infect Dis. 2005 Jan 15;191(2):278-88
15609239
J Infect Dis. 2005 Feb 1;191(3):422-34
15633102
Infect Immun. 2005 Feb;73(2):795-802
15664918
Vaccine. 2005 Mar 18;23(17-18):2082-6
15755575
Clin Diagn Lab Immunol. 2005 Jun;12(6):713-21
15939745
Infect Immun. 2005 Oct;73(10):6547-51
16177329
Infect Immun. 2005 Dec;73(12):8362-8
16299334
J Pharm Sci. 2006 Jan;95(1):80-96
16315230
Infect Immun. 2006 Jan;74(1):794-7
16369043
Vaccine. 2006 May 1;24(18):3953-63
16530302
AIDS Res Hum Retroviruses. 2006 Jun;22(6):558-68
16796531
Vaccine. 2006 Sep 29;24(40-41):6405-13
16828937
J Immunol. 2007 Apr 1;178(7):4424-35
17372000
Infect Immun. 2001 May;69(5):2888-93
11292703